Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
XSPRAY PHARMA AB (PUBL) logo — www.xspraypharma.com

XSPRAY PHARMA AB (PUBL)

www.xspraypharma.com

Founded 2003 Sweden Sweden 35 employees Post Ipo Debt Total: $100.00M Biopharma, Biotechnology +2

General Information

Company Name XSPRAY PHARMA AB (PUBL)
Founded Year 2003
Location Sweden Sweden +1
Employees 35
Industries Biopharma, Biotechnology, Health Care +1
Funding Stage Post Ipo Debt
Social

Get notified when XSPRAY PHARMA AB (PUBL) moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About XSPRAY PHARMA AB (PUBL)

Xspray Pharma (Nasdaq Stockholm: XSPRAY) is a Swedish-based pharmaceutical company founded in 2003 with the goal of enhancing patients' quality of life through the development and production of pharmaceuticals. The company specializes in utilizing innovative, patented, and scalable technology to create improved versions of existing drugs, primarily focusing on protein kinase inhibitors (PKIs) for cancer treatment. With a strong pipeline of product candidates and the HyNap technology, Xspray Pharma aims to enter the market before secondary patents expire, ensuring rapid patient benefits. The company's first product, XS0004 dasatinib, is awaiting FDA approval and has obtained orphan drug status in the US. Xspray Pharma's management team brings extensive experience in the pharmaceutical industry. The company's shares are publicly traded on Nasdaq Stockholm, and their commitment to utilizing leading-edge technology and industry expertise places them at the forefront of the Biopharma, Biotechnology, Health Care, and Pharmaceutical industries. In November 2024, Xspray Pharma secured a kr100.00M Post-IPO Debt investment from Buntel and Fenja Capital II, showcasing strong investor confidence in the company's future prospects. For more information, visit www.xspraypharma.com.

Taxonomy: Pharmaceuticals, Drug development, Innovative technology, Patented technology, Scalable technology, Clinical development, Pipeline management, Orphan drug status, Protein kinase inhibitors (PKIs), Cancer treatment, FDA approval, Management expertise, Nasdaq Stockholm listed, HyNap technology

Services & Products

Development of improved versions of protein kinase inhibitors (PKIs) for cancer treatment using innovative amorphous product development technology

Target Customers

Patients suffering from cancer and healthcare providers

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Debt •••••• 2 •••• •••• 06 Nov 2024
Series A •••••• 1 •••• •••• 05 Sep 2016

XSPRAY PHARMA AB (PUBL) Alternatives & Competitors

XSPRAY PHARMA AB (PUBL) vs
Ascendis Pharma
Ascendis Pharma Denmark

Committed to making a meaningful difference for patients

Post Ipo Debt
1046 employees
Biotechnology, Health Care
Compare XSPRAY PHARMA AB (PUBL) vs Ascendis Pharma
XSPRAY PHARMA AB (PUBL) vs
Disruptive Pharma AB
Disruptive Pharma AB Sweden

Creating a pipeline of drug products based on our novel drug delivery platform

17 employees
Manufacturing, Pharmaceutical
Compare XSPRAY PHARMA AB (PUBL) vs Disruptive Pharma AB
XSPRAY PHARMA AB (PUBL) vs
IRLAB Therapeutics AB
IRLAB Therapeutics AB Sweden

A clinical-stage biopharma discovering and developing novel treatments for the most troublesome symp...

Grant
37 employees
Health Care, Health and Wellness
Compare XSPRAY PHARMA AB (PUBL) vs IRLAB Therapeutics AB

FAQ About XSPRAY PHARMA AB (PUBL)

www.xspraypharma.com
XSPRAY PHARMA AB (PUBL) was founded in 2003.
XSPRAY PHARMA AB (PUBL) is headquartered in Sweden.
XSPRAY PHARMA AB (PUBL) operates in the following industries: Biopharma, Biotechnology, Health Care, Pharmaceutical.
XSPRAY PHARMA AB (PUBL) has approximately 35 employees.
XSPRAY PHARMA AB (PUBL) has completed 2 funding rounds, raising a total of $100.00M. The latest funding stage is Post Ipo Debt.
XSPRAY PHARMA AB (PUBL) offers: Development of improved versions of protein kinase inhibitors (PKIs) for cancer treatment using innovative amorphous product development technology.
Top alternatives and competitors to XSPRAY PHARMA AB (PUBL) include Ascendis Pharma, Disruptive Pharma AB, IRLAB Therapeutics AB, Klus Pharma Inc., Enorama Pharma. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
XSPRAY PHARMA AB (PUBL) and Ascendis Pharma are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors XSPRAY PHARMA AB (PUBL) and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy